Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and at last count has given invited lectures in 33 countries.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).
Disclosures
CONSULTANT: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Merck, Moyvant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics.
Grant/Research Support: Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio.
Recent Contributions to PracticeUpdate:
- Thromboembolic Risk With Androgen Deprivation Therapy in Prostate Cancer
- Genetic Testing in Patients With Relevant Family History in Prostate Cancer
- Inherited Mutations in DNA-Repair Genes in Metastatic Prostate Cancer
- Predictive Biomarkers for Prostate Cancer Treatment Selection
- AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker for Outcomes in Castration-Resistant Prostate Cancer
- AUA: <i>BRCA</i> Mutations May Play Role in Prostate Cancer
- Severe Neutropenia During Cabazitaxel Treatment Is Associated With Survival Benefit in Men With Metastatic Castration-Resistant Prostate Cancer
- Increased Risk of Colorectal Cancer After Prostate Cancer
- Enzalutamide for Older Patients With Metastatic Castration-Resistant Prostate Cancer
- Evaluating an Elevated Screening PSA Test